David Schenkein
@schenkeinGeneral Partner @GVteam Hematologist/Medical Oncologist
Similar User
@timmermanreport
@JebKeiper
@michael_gilman
@JMaraganore
@john_evans3
@rtnarch
@KymeraTx
@KapellerRosana
@BentheFidler
@MikeNGladstone
@FishburnSimone
@cngarabedian
@drcwestphal
@SaraNayeem
@NelloMainolfi
Congratulations to Sarah and the entire @AgiosPharma team for this great accomplishment
We completed enrollment of our Phase 3 RISE UP trial in #sicklecelldisease. The topline results from this 52-week study are expected in late 2025. Read more: investor.agios.com/news-releases/…
Exciting collaboration with @bmsnews to develop suite of new medicines- congratulations to @PrimeMedicine and @bmsnews investors.primemedicine.com/news-releases/…
Thrilled to be working with this amazing group of people and excited by the impact we are and will be making in some many important areas in digital and healthcare.
Happy 15th birthday, @gvteam! 🎂Thanks to @FortuneMagazine's @agarfinks for spending time with us, as we celebrate GV's history, and look toward the next 300 years... 🚀
Incredibly proud of both the @AgiosPharma and @ServierPharma teams- changing the landscape for patients with IDH glioma- great day for these patients
We're thrilled to share the FDA has approved vorasidenib, representing a significant step forward for patients. Congrats to @ServierPharma and the Agios team for their early discovery and development efforts. Read more: investor.agios.com/news-releases/…
Congrats to the Santa Ana team and to Brendan Bulik-Sullivan for leading the round for @GVteam
Welcome to GV, Santa Ana Bio! We're thrilled to lead Santa Ana Bio's Series B as the company furthers the development of targeted therapies for patients with autoimmune and inflammatory diseases. Learn more about today's news in @FierceBiotech — fiercebiotech.com/biotech/inflam…
Congratulations to everyone @AgiosPharma on the second positive phase 3 trial in thalassemia- terrific news for patients
We're pleased to announce the global Ph. 3 ENERGIZE-T study in adults with transfusion-dependent alpha- or beta-#thalassemia achieved its primary endpoint of transfusion reduction response with potential to become a novel advancement in care for patients. investor.agios.com/news-releases/…
Huge congrats to the entire @AgiosPharma team for a fabulous deal with Royalty Pharma
Agios has agreed to sell rights to our 15% royalty on potential U.S. net sales of Servier’s vorasidenib to Royalty Pharma. This deal boosts our financial independence for future PYRUKYND® launches and pipeline expansion. investor.agios.com/news-releases/…
Congratulations to Mike Fried and the entire team for a fabulous season
Welcome to the team @elena_sakach - excited to be working with you
We're excited to announce @elena_sakach as our newest investment partner in SF! Elena will lead investments across fintech, software, and AI. We’re incredibly excited to see her impact at GV and across the portfolio. Welcome to the team! bit.ly/4bme0ws
Congrats to the entire @agiospharma team for the incredible progress and the plenary talk at #EHA2024
We’re excited to participate in #EHA2024! Seven abstracts led by our team and external collaborators will be presented and/or published, including data from our Phase 3 ENERGIZE study in non-transfusion-dependent #thalassemia within a plenary session. investor.agios.com/news-releases/…
I’ve been doing 20VC for 10 years. There have been good times, there have been bad times. Through all of them, @Thulme has been there for me. He is one of the greats, and this show was a result of years in friendship. My top lessons 👇
We are so excited to work with Kevin and his team on a completely novel approach to cancer therapy with the potential to help patients with cancer
“We’re flipping the script, doing the exact opposite of the past 30 years. That’s bold and grounded in bedrock data.” Congrats to GV entrepreneur in residence @marksy11 on the launch of Delphia and pioneering activation lethality to improve cancer care — bit.ly/3xTOHTB
Congratulations to the amazing team @PrimeMedicine for their tremendous work to move prime editing from an exciting academic discovery into a product ready for clinical trials to help patients with chronic granulomatous disease
We are pleased to announce that #FDA has cleared our IND application for PM359 for the treatment of chronic granulomatous disease (CGD), enabling Prime to initiate its Phase 1/2 clinical trial in the US. Details: investors.primemedicine.com/news-releases/… $PRME
Terrific to have Nicole join the team-fabulous scientist, leader and person and she will make a huge impact on patients through her work
We're excited to announce @NicoleGaudelli as GV’s newest life sciences entrepreneur in residence! 🎉🧬 As an esteemed scientist and Adenine Base Editing inventor, Nicole will advance next-generation genomic medicines. Learn more in @Forbes ➡️ forbes.com/sites/katiejen…
Congratulations Anthony- I am so excited to work with you on the @GVteam
GV is delighted to announce physician, genomicist, and data scientist Anthony Philippakis as our newest general partner in Cambridge! 🎉 Anthony and @kyeshwant spoke to @BioPharmaDive about the news and the opportunities ahead for precision medicine — biopharmadive.com/news/gv-anthon…
has science yet discovered that the cilantro soap people do not have a genetic variant and are instead just...... being silly!?
Congratulations to the entire @accent_tx team on their great work
The team at @accent_tx is pioneering a new class of precision cancer therapies for patient impact. Learn more about the company’s work to drive critical programs forward 👇 — bit.ly/42eEvQJ
Congratulations to Karthik, @KJSidz and Sherry on their promotion- so well deserved and thrilled to work alongside them everyday.
Congratulations to the entire @AgiosPharma team for this exciting result that will help patients around the globe with thalassemia- so proud
The Phase 3 ENERGIZE study in non-transfusion-dependent (NTD) #thalassemia hit its primary endpoint of hemoglobin response! Join our investor webcast at 8 a.m. ET for more on why this announcement is exciting for patients and the #raredisease community: investor.agios.com/news-releases/…
Congrats to the entire @AgiosPharma team
United States Trends
- 1. Jake Paul 979 B posts
- 2. #Arcane 235 B posts
- 3. Jayce 53,3 B posts
- 4. Good Saturday 3.217 posts
- 5. #SaturdayVibes 3.238 posts
- 6. Serrano 249 B posts
- 7. #saturdaymorning 2.169 posts
- 8. #PlutoSeriesEP5 144 B posts
- 9. Pence 82,6 B posts
- 10. AioonMay Limerence 120 B posts
- 11. Vander 17,4 B posts
- 12. #SaturdayMood 1.614 posts
- 13. maddie 21,7 B posts
- 14. Caturday 7.651 posts
- 15. WOOP WOOP 1.447 posts
- 16. IT'S GAMEDAY 6.358 posts
- 17. John Oliver 14,6 B posts
- 18. Fetterman 37,4 B posts
- 19. Father Time 10,9 B posts
- 20. $XRP 87,8 B posts
Who to follow
-
Timmerman Report
@timmermanreport -
Jeb Keiper
@JebKeiper -
Michael Gilman
@michael_gilman -
John Maraganore 🇺🇦🇮🇱
@JMaraganore -
John Evans
@john_evans3 -
Robert Nelsen
@rtnarch -
Kymera Therapeutics
@KymeraTx -
Rosana Kapeller
@KapellerRosana -
Ben Fidler
@BentheFidler -
Michael Gladstone
@MikeNGladstone -
Simone Fishburn 🎗️
@FishburnSimone -
Chris Garabedian
@cngarabedian -
Christoph Westphal
@drcwestphal -
Sara Nayeem
@SaraNayeem -
Nello Mainolfi
@NelloMainolfi
Something went wrong.
Something went wrong.